KAZUISTIKY Advanced heart failure and cardiac arrhythmia in a young adult survivor of childhood cancer E22 | VNITŘNÍ LÉKAŘSTVÍ / Vnitř Lék 2022;68(1):E22-E26 / www.casopisvnitrnilekarstvi.cz Advanced heart failure and cardiac arrhythmia in a young adult survivor of childhood cancer Xénia Faktorová1, Milan Luknár2,3, Zuzana Zelinková1, Lucia Horniaková4, Eva Mikušková5, Michal Šašov6, Mária Szántová4, ViliamMojto4, Beata Mladosievičová7 1Department of Internal Medicine of the Slovak Medical University, University Hospital – St. Michael’s Hospital, a.s, Bratislava 2Department of Heart Failure and Heart Transplantation National Institute of Cardiovascular Diseases, Bratislava 3Department of Cardiology, Faculty of Medicine, Comenius University and National Institute of Cardiovascular Diseases, Bratislava 43rd Department of Internal Medicine, Faculty of Medicine, Comenius University and University Hospital, Bratislava 5Department of Oncohematology Faculty of Medicine, Comenius University and National Cancer Institute, Bratislava 6Department of Arrhytmias and Cardiac Stimulation National Institute of Cardiovascular Diseases, Bratislava 7Institute of Pathological Physiology, Department of Clinical Pathophysiology, Faculty of Medicine, Comenius University, Bratislava The goal of this case report is to describe the young childhood cancer survivor whowas treated for non‑Hodgkin lymphoma with chemotherapy containing anthracycline doxorubicin and who developed symptoms of serious cardiovascular dam‑ age 27 years after diagnosis of cancer. The patient is in long‑term complete remission of the lymphoma. He started guideline medical therapies for chronic heart failure and had a cardioverter defibrillator implanted for primary prevention of sudden cardiac death. He is currently a candidate for heart transplantation. Key words: anthracyclines, arrhythmia, heart failure, implantable cardioverter defibrillator, late cardiotoxicity. Závažné zlyhávanie srdca a arytmia po protinádorovej liečbe podávanej v detstve Cieľom kazuistiky je popísať prípad mladého pacienta, v detstve úspešne liečeného pre non-Hodgkinov lymfóm chemotera‑ piou s obsahom anthracyklínu doxorubicínu s neskorším rozvojom príznakov závažného kardiovaskulárneho poškodenia 27 rokov od diagnostiky lymfómu. Pacient je dlhodobo v kompletnej remisii onkologického ochorenia. U pacienta bola započatá liečba chronického srdcového zlyhávania v súlade s najnovšími odporúčaniami vrátane implantácie kardioverter-defibrilátora, ako primárnej prevencie náhlej kardiálnej smrti. Momentálne je pacient čakateľom na transplantáciu srdca. Kľúčové slová: antracyklíny, arytmia, srdcové zlyhávanie, implantovateľný kardioverter-defibrilátor, neskorá kardiotoxicita. Introduction Every year, 15 million people worldwide are diagnosed with cancer, of which about 300.000 are children. In developed countries, more than 2/3 of paediatric cancer patients have been cured in the last two decades and for some diagnoses (e.g., haematology‑oncological malignancies) the number of patients treated is even higher. However, 60% of paediatric cancer survivors experience serious or less serious long‑term and late adverse health outcomes after the cancer treatment. Serious late outcomes after a multiyear latent period also include cardiovascular (CV) complications (1). In cardiology practice, childhood cancer survivors KORESPONDENČNÍ ADRESA AUTORA: MUDr. Xénia Faktorová, xenia.faktorova@gmail.com Interná klinika SZU, Univerzitná Nemocnica – Nemocnica svätého Michala, a.s. Satinského 1, 833 08 Bratislava Cit. zkr: Vnitř Lék 2022;68(1):E22-E26 Článek přijat redakcí: 29. 11. 2021 Článek přijat po recenzích: 24. 1. 2022
RkJQdWJsaXNoZXIy NDA4Mjc=